124 related articles for article (PubMed ID: 10510056)
1. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin.
Song X; Huhle G; Wang L; Hoffmann U; Harenberg J
Circulation; 1999 Oct; 100(14):1528-32. PubMed ID: 10510056
[TBL] [Abstract][Full Text] [Related]
2. Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia.
Harenberg J; Huhle G; Wang LC; Hoffmann U; Song XH
Br J Haematol; 2000 May; 109(2):360-3. PubMed ID: 10848825
[TBL] [Abstract][Full Text] [Related]
3. Interference of thrombin in immunological assays for hirudin specific antibodies.
Hamilton RG; Levy JH; Marder VJ; Sane DC
J Immunol Methods; 2012 Jul; 381(1-2):50-8. PubMed ID: 22542931
[TBL] [Abstract][Full Text] [Related]
4. Treatment of an acute flush reaction caused by subcutaneous r-hirudin with pegylated hirudin.
Harenberg J; Hoffmann U; Huhle G; Song XH; Wang LC
Br J Haematol; 2000 Mar; 108(3):528-30. PubMed ID: 10759710
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.
Harenberg J; Jörg I; Fenyvesi T; Piazolo L
J Thromb Thrombolysis; 2005 Feb; 19(1):65-9. PubMed ID: 15976970
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG.
Untch B; Ahmad S; Jeske WP; Messmore HL; Hoppensteadt DA; Walenga JM; Lietz H; Fareed J
Thromb Res; 2002 Jan; 105(2):117-23. PubMed ID: 11958801
[TBL] [Abstract][Full Text] [Related]
7. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia.
Juhl D; Eichler P; Lubenow N; Strobel U; Wessel A; Greinacher A
Eur J Haematol; 2006 May; 76(5):420-6. PubMed ID: 16466367
[TBL] [Abstract][Full Text] [Related]
8. A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study.
Huhle G; Hoffmann U; Hoffmann I; Liebe V; Harenberg JF; Heene DL
Thromb Res; 2000 Aug; 99(4):325-34. PubMed ID: 10963783
[TBL] [Abstract][Full Text] [Related]
9. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.
Eichler P; Friesen HJ; Lubenow N; Jaeger B; Greinacher A
Blood; 2000 Oct; 96(7):2373-8. PubMed ID: 11001886
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
Huhle G; Hoffmann U; Hoffmann I; Harenberg J; Heene DL
Dtsch Med Wochenschr; 2000 Jun; 125(22):686-91. PubMed ID: 10874895
[TBL] [Abstract][Full Text] [Related]
11. Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma halflife.
Huhle G; Liebe V; Hudek R; Heene DL
Thromb Haemost; 2001 May; 85(5):936-8. PubMed ID: 11372692
[No Abstract] [Full Text] [Related]
12. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin.
Huhle G; Geberth M; Hoffmann U; Heene DL; Harenberg J
Gynecol Obstet Invest; 2000; 49(1):67-9. PubMed ID: 10629377
[TBL] [Abstract][Full Text] [Related]
13. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment.
Huhle G; Hoffmann U; Song X; Wang LC; Heene DL; Harenberg J
Br J Haematol; 1999 Jul; 106(1):195-201. PubMed ID: 10444187
[TBL] [Abstract][Full Text] [Related]
14. Treatment of heparin-induced thrombocytopenia.
Greinacher A
Thromb Haemost; 1999 Aug; 82(2):457-67. PubMed ID: 10605737
[No Abstract] [Full Text] [Related]
15. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.
Greinacher A; Völpel H; Janssens U; Hach-Wunderle V; Kemkes-Matthes B; Eichler P; Mueller-Velten HG; Pötzsch B
Circulation; 1999 Jan 5-12; 99(1):73-80. PubMed ID: 9884382
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of subcutaneous hirudins.
Deitcher SR
Am J Health Syst Pharm; 2003 Oct; 60 Suppl 5():S27-31. PubMed ID: 14593980
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient.
Nowak G; Bucha E; Brauns I; Czerwinski R
Wien Klin Wochenschr; 1997 May; 109(10):354-8. PubMed ID: 9200807
[TBL] [Abstract][Full Text] [Related]
18. [Management of HIT II patients with hirudin antibodies after primary therapy].
Harenberg J
Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Apr; 37 Suppl 1():S8-11. PubMed ID: 11973671
[No Abstract] [Full Text] [Related]
19. Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotype antibodies.
Selleng K; Warkentin TE; Sheppard JA; Greinacher A
Transfusion; 2009 Sep; 49(9):1812-8. PubMed ID: 19497062
[TBL] [Abstract][Full Text] [Related]
20. Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients.
Ahmad S; Bacher HP; Lassen MR; Hoppensteadt DA; Leitz H; Misselwitz F; Walenga JM; Fareed J
Arch Pathol Lab Med; 2003 May; 127(5):584-8. PubMed ID: 12708902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
